Amanta Healthcare Ltd
Incorporated in December 1994, Amanta Healthcare Limited is a pharmaceutical company that specializes in the development, manufacturing, and marketing of a diverse array of sterile liquid products.[1]
- Market Cap ₹ 520 Cr.
- Current Price ₹ 132
- High / Low ₹ 155 / 92.0
- Stock P/E 31.6
- Book Value ₹ 56.7
- Dividend Yield 0.00 %
- ROCE 11.6 %
- ROE 10.4 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 22.4% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 10.9% over past five years.
- Company has a low return on equity of 10.1% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 184 | 171 | 225 | 259 | 280 | 275 | 288 | |
| 147 | 133 | 173 | 206 | 223 | 215 | 228 | |
| Operating Profit | 37 | 38 | 52 | 53 | 58 | 60 | 60 |
| OPM % | 20% | 22% | 23% | 20% | 21% | 22% | 21% |
| 2 | 1 | 76 | 4 | 1 | 1 | 1 | |
| Interest | 38 | 40 | 49 | 35 | 34 | 28 | 21 |
| Depreciation | 16 | 17 | 17 | 18 | 20 | 18 | 19 |
| Profit before tax | -15 | -18 | 62 | 3 | 5 | 15 | 21 |
| Tax % | 25% | 23% | 11% | 179% | 32% | 29% | 30% |
| -19 | -22 | 55 | -2 | 4 | 10 | 15 | |
| EPS in Rs | -7.03 | -8.14 | 20.54 | -0.79 | 1.35 | 3.64 | 3.83 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 4% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | 114% |
| TTM: | 56% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | 10% |
| Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 27 | 27 | 27 | 27 | 29 | 39 |
| Reserves | 2 | -20 | 36 | 36 | 39 | 68 | 181 |
| 231 | 235 | 226 | 216 | 211 | 204 | 244 | |
| 127 | 150 | 104 | 96 | 75 | 81 | 93 | |
| Total Liabilities | 388 | 392 | 392 | 374 | 352 | 382 | 558 |
| 244 | 242 | 240 | 232 | 228 | 217 | 207 | |
| CWIP | 0 | 0 | 0 | 9 | 0 | 7 | 82 |
| Investments | 0 | 2 | 3 | 0 | 4 | 8 | 7 |
| 144 | 149 | 149 | 133 | 120 | 150 | 262 | |
| Total Assets | 388 | 392 | 392 | 374 | 352 | 382 | 558 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 38 | 31 | 62 | 43 | 58 | 47 | 48 | |
| -9 | -13 | -6 | -7 | -10 | -24 | -94 | |
| -37 | -18 | -50 | -42 | -46 | -23 | 126 | |
| Net Cash Flow | -8 | -0 | 6 | -6 | 1 | -1 | 81 |
| Free Cash Flow | 27 | 19 | 52 | 36 | 46 | 26 | -32 |
| CFO/OP | 102% | 66% | 119% | 93% | 111% | 84% | 93% |
Ratios
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 110 | 73 | 75 | 63 | 67 | 55 |
| Inventory Days | 225 | 422 | 338 | 247 | 309 | 464 | 312 |
| Days Payable | 99 | 186 | 185 | 130 | 129 | 194 | 136 |
| Cash Conversion Cycle | 229 | 345 | 226 | 193 | 243 | 336 | 231 |
| Working Capital Days | 51 | -5 | 28 | 42 | 16 | 26 | 6 |
| ROCE % | 9% | 14% | 13% | 14% | 15% | 12% |
Insights
In beta| Mar 2017 | Mar 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Installed Capacity - Large Volume Parenterals (LVP) Lakh Bottles per Annum |
|
|||||
| Installed Capacity - Small Volume Parenterals (SVP) Lakh Bottles per Annum |
||||||
| Capacity Utilization - Total % |
||||||
| Commercialized Products (Portfolio Size) Count |
||||||
| Capacity Utilization - LVP % |
||||||
| Capacity Utilization - SteriPort % |
||||||
| Capacity Utilization - SVP % |
||||||
| Installed Capacity - SteriPort Lakh Bottles per Annum |
||||||
| Total Workforce (Employees + Contractual) Count |
||||||
| Number of Distributors Count |
||||||
| Product Registrations (International) Count |
||||||
Extracted by Screener AI
Documents
Announcements
-
Intimation For Commissioning Of Solar Power Plant For Captive
Consumption
30 May - 10.8 MWp solar power plant commissioned in Kheda; generation started May 30, 2026 for captive use.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Amanta Healthcare filed FY26 secretarial compliance report; no major non-compliances noted.
-
Statement Of Deviation Or Variation In Utilization Of Funds, If Any
29 May - No deviation in use of ₹126 crore IPO proceeds for quarter ended December 31, 2025.
-
Statement Of Deviation Or Variation In Utilization Of Funds, If Any.
29 May - Reported no deviation in IPO proceeds for quarter ended March 31, 2026; ₹126 crore raised.
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 21 May
Concalls
-
May 2026Transcript PPT
-
Feb 2026Transcript PPT
Business Profile[1][2]
Amanta Healthcare manufactures sterile liquid products, mainly parenteral medications administered through injections or infusions. Their production utilizes advanced technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM). The company operates in six therapeutic areas, including fluid therapy, ophthalmics, respiratory care, and irrigation solutions, plus a medical device segment.